My experience with the SEC taught me how important the nuances and industry experience are to public offerings.
About Darren
Darren DeStefano primarily represents private and public corporate clients and investment banking firms with a particular emphasis on public securities matters. He has handled a variety of significant business transactions, including public and private equity offerings, high yield and convertible debt financings and mergers and acquisitions. In addition, he also represents a number of venture capital and private equity funds in connection with their investing activities and securities compliance matters. He has represented publicly traded and privately held companies in a wide variety of industries, including biotechnology, medical devices, pharmaceuticals and information technology.
Luna Innovations Gets $50 Million Investment From White Hat, Acquires Silixa
December 21, 2023
Cooley advised Luna Innovations, a global leader in advanced fiber optic-based technology, on its $50 million investment from White Hat Capital Partners and its acquisition of Silixa.
Cara Therapeutics, Inc. -- $40 Million Royalty Interest Purchase and Sale Agreement
November 3, 2023
Cooley advised Cara Therapeutics, Inc. on its $40 million royalty interest purchase and sale agreement with HealthCare Royalty Partners. Michael Tollini and Addison Pierce led the Cooley team advising Cara, which included Bin Wang, Xueqing Li and Jordan Verrilli. Cara, which trades on The NASDAQ Global Market as “CARA,” is a clinical-stage biotech company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors.
TriSalus Life Sciences Completes Merger With MedTech Acquisition Corporation
August 16, 2023
Cooley advised TriSalus Life Sciences, an oncology company with a focus on treatments for patients with liver and pancreatic tumors, on its merger with MedTech Acquisition Corporation.
ACELYRIN Announces Pricing of Upsized Initial Public Offering
May 15, 2023
Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.
Thayer Ventures Acquisition Corp. Completes Merger With Inspirato
February 19, 2022
Cooley advised Thayer Ventures Acquisition Corp., a publicly traded special purpose acquisition company affiliated with Thayer Ventures, on its completed business combination with innovative luxury travel subscription brand Inspirato. Lawyers Daniel Peale, John McKenna, Milson Yu, Michelle Peleg, Shawn Fateh, Jonathan Camello, Brian Kloeblen and Angel Nwachukwu led the Cooley team advising Thayer Ventures.